文献速递胸部肿瘤

HER2介导的细胞毒药物内化在ERBB2扩增或突变肺癌中的作用

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
PubMed 文献 · Cancer Discov · 2020-03-25

该研究在肺癌细胞系和患者来源异种移植模型中证实,HER2泛素化和内化而非过表达是抗HER2抗体药物偶联物(ADC)T-DM1和T-DXd内吞及疗效的关键机制。临床试验中T-DM1在49例ERBB2扩增或突变肺癌患者中达到51%的缓解率。与不可逆泛HER抑制剂联用可增强受体泛素化、ADC内化及疗效,而切换至携带不同细胞毒载荷的T-DXd可在T-DM1耐药患者中实现持久缓解。

要点

  • HER2泛素化和内化是ADC疗效的关键机制,而非单纯过表达。
  • T-DM1在ERBB2扩增或突变肺癌中客观缓解率达51%。
  • 联合不可逆泛HER抑制剂或切换T-DXd可增强疗效并克服耐药。

核心结论

  • HER2泛素化和内化是T-DM1和T-DXd在ERBB2扩增或突变肺癌中内吞及疗效的关键机制。
  • T-DM1在ERBB2扩增或突变肺癌患者中具有临床疗效,缓解率为51%。
  • 与不可逆泛HER抑制剂联用可增强受体泛素化、ADC内化及疗效。
  • 切换至携带不同细胞毒载荷的T-DXd可在T-DM1耐药患者中实现持久缓解。

研究设计与样本

  • 研究使用肺癌细胞系和患者来源异种移植模型进行机制探索。
  • 临床试验中T-DM1治疗49例ERBB2扩增或突变肺癌患者。

主要发现

  • HER2泛素化和内化而非过表达是ADC内吞和疗效的关键机制。
  • T-DM1在49例ERBB2扩增或突变肺癌患者中缓解率为51%。
  • 与不可逆泛HER抑制剂联用增强受体泛素化、ADC内化及疗效。
  • ADC切换至T-DXd在T-DM1耐药患者及相应异种移植模型中实现持久缓解。

关键数值与推荐

  • T-DM1在49例ERBB2扩增或突变肺癌患者中缓解率为51%。

临床怎么用

  • T-DM1可用于ERBB2扩增或突变肺癌的治疗。
  • 与不可逆泛HER抑制剂联用可能增强ADC疗效。
  • 对T-DM1耐药者可考虑切换至T-DXd。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Amplification of and oncogenic mutations in ERBB2, the gene encoding the HER2 receptor tyrosine kinase, promote receptor hyperactivation and tumor growth. Here we demonstrate that HER2 ubiquitination and internalization, rather than its overexpression, are key mechanisms underlying endocytosis and consequent efficacy of the anti-HER2 antibody-drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) in lung cancer cell lines and patient-derived xenograft models. These data translated into a 51% response rate in a clinical trial of T-DM1 in 49 patients with ERBB2-amplified or -mutant lung cancers. We show that cotreatment with irreversible pan-HER inhibitors enhances receptor ubiquitination and consequent ADC internalization and efficacy. We also demonstrate that ADC switching to T-DXd, which harbors a different cytotoxic payload, achieves durable responses in a patient with lung cancer and corresponding xenograft model developing resistance to T-DM1. Our findings may help guide future clinical trials and expand the field of ADC as cancer therapy. SIGNIFICANCE: T-DM1 is clinically effective in lung cancers with amplification of or mutations in ERBB2. This activity is enhanced by cotreatment with irreversible pan-HER inhibitors, or ADC switching to T-DXd. These results may help address unmet needs of patients with HER2-activated tumors and no approved targeted therapy.See related commentary by Rolfo and Russo, p. 643.This article is highlighted in the In This Issue feature, p. 627.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Li BT, Michelini F, Misale S, et al. HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer Discov. 2020. PMID: 32213539. doi:10.1158/2159-8290.CD-20-0215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。